RHBC
TCON

R.H. Bluestein & Co’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

R.H. Bluestein & Co’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50
Closed -$34K – 341
2017
Q4 		$34K Sell
50
-30
-38% -$18.1K ﹤0.01% 316
2017
Q3 		$50K Hold
80
– – ﹤0.01% 318
2017
Q2 		$38K Buy
+80
New +$48.8K ﹤0.01% 308

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

R.H. Bluestein & Co's TCON Position: Q1 2018 in Review

R.H. Bluestein & Co sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2018, closing a stake of 50 shares — an estimated $34K sold.

R.H. Bluestein & Co first reported a position in TCON in Q2 2017 and held it in 3 quarters. The position peaked at $50K in Q3 2017. 33 funds tracked by Wall St. Rank hold TCON as of Q1 2018.

  • R.H. Bluestein & Co reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • R.H. Bluestein & Co sold 50 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $34K.
  • R.H. Bluestein & Co first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • R.H. Bluestein & Co's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q3 2017.
  • 33 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on R.H. Bluestein & Co's 13F filing for Q1 2018, filed 10 May 2018.